Featuring an interview with Dr Hanny Al-Samkari, including the following topics:
- Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00)
- Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32)
- Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52)
- Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46)